Fresenius: Bryan Garnier raises target price.

(CercleFinance.com) - Bryan Garnier has confirmed its "buy" recommendation on Fresenius and has raised its fair value for the stock from 82 euros to 87 euros, believing that recent acquisitions reinforce the German group's long-term visibility and defensive profile.


The broker also welcomes the provider of medical devices' acquisition of Akorn, which will reinforce Kabi's product portfolio in the US and will provide it with a new sales channel.

"...entry into the biosimilar business, expected to surpass USD20bn towards 2022, positions KABI for the next decade," Bryan Garnier adds.

"Quirónsalud is off to a strong start to the year, and despite some volatility in Q3, FY guidance might prove to be conservative," it continues.


Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.